ChemicalBook > CAS DataBase List > Lapatinib ditosylate

Lapatinib ditosylate

Product Name
Lapatinib ditosylate
CAS No.
388082-78-8
Chemical Name
Lapatinib ditosylate
Synonyms
Lapatinib ditosylate Monohydrate;Lapatinib tosilate;Lapatinib ditosylate hydrate;Lapatinb;GW2016 ditosylate;GW-572016;GW572016;(E)-Ferulic acid-d;lapatinib(GW572016);Lapatinib Ditosilate;Lapatinib ditosylate
CBNumber
CB2966227
Molecular Formula
C41H40ClFN4O11S3
Formula Weight
925.46
MOL File
388082-78-8.mol
More
Less

Lapatinib ditosylate Property

Melting point:
>200oC (dec.)
storage temp. 
under inert gas (nitrogen or Argon) at 2-8°C
solubility 
DMSO (Slightly), Methanol (Slightly)
form 
Solid
color 
Yellow
CAS DataBase Reference
388082-78-8(CAS DataBase Reference)
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

N-Bromosuccinimide Price

TRC
Product number
L175813
Product name
LapatinibDitosylateMonohydrate
Packaging
10mg
Price
$85
Updated
2021/12/16
Usbiological
Product number
281198
Product name
Lapatinib ditosylate
Packaging
50mg
Price
$375
Updated
2021/12/16
Usbiological
Product number
015474
Product name
Lapatinib Ditosylate
Packaging
5mg
Price
$425
Updated
2021/12/16
Matrix Scientific
Product number
090594
Product name
Lapatinib ditosylate hydrate
Purity
98%
Packaging
250mg
Price
$567
Updated
2021/12/16
Biorbyt Ltd
Product number
orb180754
Product name
Lapatinib ditosylate
Purity
>98%
Packaging
250mg
Price
$615.4
Updated
2021/12/16
More
Less

Lapatinib ditosylate Chemical Properties,Usage,Production

Uses

anticancer

Uses

binds to a(1), dopamine, histamine H1, muscarinic, and serotonin type 2 (5-HT2) receptors atypical antipsychotic agent

Uses

Lapatinib ditosylate monohydrate is a form of Lapatinib I, an orally active drug for breast cancer as a dual EGFR and erbB-?2 inhibitor.

Definition

ChEBI: Lapatinib ditosylate monohydrate is a member of quinazolines.

General Description

Lapatinib is available in 250-mg tablets for oral administrationand is used in combination with cabecitabine in thetreatment of breast cancer for those patients that over expressthe type 2 EGF-R and who have previously receivedtaxane, anthracycline, and trastuzumab therapy. The type 2EGF-R is one subtype of this receptor and is also known asHER2 or ErbB-2. The agent is a receptor TK inhibitor targetingthe ErbB-1 and ErbB-2 subtypes. Binding occurs atthe ATP-binding site and thereby prevents phosphorylationand the subsequent activation of other kinase enzymes.ErbB-1 overexpression occurs in approximately27% to 30% of breast cancers, while ErbB-2 is over expressedin 20% to 25% of cases.The agent has demonstratedIC50 values of ＜0.2μM against ErbB-1 and 2 fromseveral different cancer cell lines and dissociates slowly(t1/2＝300 min) from these receptor TKs.The drug isboth a substrate and an inhibitor of the efflux transportersPgp and BCRP. It is also an inhibitor of the hepatic uptaketransporter OATP1B1, which is an organic anion transporter.The absorption of lapatinib is incomplete andvariable after oral administration. The agent is extensivelymetabolized by CYP3A4 and CYP3A5, with minor contributionsfrom CYP2C19 and CYP2C8. Lapatinib inhibitsCYP3A and CYP2C8 at clinically relevant concentrations.The agent is highly (99%) protein bound and eliminatedprimarily in the feces. The half-life of the agent increaseupon repeated dosing, taking 6 days to reach steady statethat gives an effective half-life of 24 hours. The most commonlyseen adverse effects of lapatinib therapy are skinrash and diarrhea. Skin rash is commonly seen with manyof the other TK inhibitors and agents that target ErbB-1.Lapatinib-induced diarrhea is usually mild to moderate.There have been reports of decreases in left ventricularejection fraction associated with the agent, although thisappears to occur only rarely and is reversible upon discontinuationof therapy.

target

EGFR

Lapatinib ditosylate Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Lapatinib ditosylate Suppliers

Canada 1 China 310 Europe 1 Germany 1 India 14 The Netherlands 1 United Kingdom 5 United States 24 Global 357
LGM Pharma
Tel
1-(800)-881-8210
Fax
615-250-9817
Email
inquiries@lgmpharma.com
Country
United States
ProdList
2123
Advantage
70
HBCChem, Inc.
Tel
+1-510-219-6317
Fax
+1-650-486-1361
Email
sales@hbcchem.com
Country
United States
ProdList
10648
Advantage
60
Target molecule Corp.
Tel
857-239-0968
Fax
857-239-8801
Email
service1@targetmol.com
Country
United States
ProdList
2559
Advantage
60
TargetMol Chemicals Inc.
Tel
+1-781-999-5354 +1-00000000000
Email
marketing@targetmol.com
Country
United States
ProdList
32165
Advantage
58
Cato Research Chemicals Inc.
Tel
020-81215950 4000-868-328
Email
customer@uwalab.com
Country
United States
ProdList
10404
Advantage
58
Alchem Pharmtech,Inc.
Tel
8485655694
Email
sales@alchempharmtech.com
Country
United States
ProdList
63687
Advantage
58
Protheragen-ING
Tel
+16313385890
Email
info@protheragen-ing.com
Country
United States
ProdList
3868
Advantage
58
TargetMol Chemicals Inc.
Tel
+8613564774135
Email
zijue.cai@tsbiochem.com
Country
United States
ProdList
19885
Advantage
58
TargetMol Chemicals Inc.
Tel
Email
support@targetmol.com
Country
United States
ProdList
38632
Advantage
58
Aladdin Scientific
Tel
+1-+1(833)-552-7181
Email
sales@aladdinsci.com
Country
United States
ProdList
57505
Advantage
58
CarboMer, Inc.
Tel
--
Fax
--
Email
sales@carbomer.com
Country
United States
ProdList
4026
Advantage
67
LC Laboratories
Tel
--
Fax
--
Email
custserv@lclabs.com
Country
United States
ProdList
503
Advantage
50
CAMBREX CHARLES CITY INC
Tel
--
Fax
--
Email
abby.roetman@cambrex.com
Country
United States
ProdList
35
Advantage
58
Matrix Scientific
Tel
--
Fax
--
Email
sales@matrixscientific.com
Country
United States
ProdList
6632
Advantage
80
Acanthus Research
Tel
--
Fax
--
Email
inquiries@acanthusresearch.com
Country
United States
ProdList
46
Advantage
50
SynFine Research
Tel
--
Fax
--
Email
research@synfine.com
Country
United States
ProdList
1024
Advantage
68
ChemieTek
Tel
--
Fax
--
Email
info@chemietek.com
Country
United States
ProdList
219
Advantage
50
LKT Laboratories, Inc.
Tel
--
Fax
--
Email
info@lktlabs.com
Country
United States
ProdList
2164
Advantage
64
Tecoland Corporation
Tel
--
Fax
--
Email
info@tecoland.com
Country
United States
ProdList
275
Advantage
50
Tinib-Tools
Tel
--
Fax
--
Country
United States
ProdList
164
Advantage
0
Santa Cruz Biotechnology, Inc.
Tel
--
Fax
--
Email
scbt@scbt.com
Country
United States
ProdList
3597
Advantage
60
Rintech, Inc.
Tel
--
Fax
--
Email
info@rintechinc.com
Country
United States
ProdList
3416
Advantage
60
Waterstone Technology, LLC
Tel
--
Fax
--
Email
sales@waterstonetech.com
Country
United States
ProdList
6786
Advantage
30
Beta Pharma, Inc.
Tel
--
Fax
--
Email
sales@betapharma.com
Country
United States
ProdList
6226
Advantage
60
More
Less

View Lastest Price from Lapatinib ditosylate manufacturers

HangZhou RunYan Pharma Technology Co.,LTD.
Product
Lapatinib ditosylate 388082-78-8
Price
US $0.00-0.00/g
Min. Order
1g
Purity
99% HPLC
Supply Ability
10000
Release date
2024-09-17
WUHAN FORTUNA CHEMICAL CO., LTD
Product
Lapatinib ditosylate 388082-78-8
Price
US $0.00/Kg/Bag
Min. Order
1KG
Purity
99%min
Supply Ability
1000G
Release date
2021-07-23
Nanjing Fred Technology Co., Ltd
Product
Lapatinib Ditosylate 388082-78-8
Price
US $0.00-0.00/kg
Min. Order
1kg
Purity
99%，single impurity＜0.1
Supply Ability
1 ton
Release date
2023-12-29

388082-78-8, Lapatinib ditosylateRelated Search:

Lapatinib PENTA(ETHYLENE GLYCOL) DI-P-TOLUENESULFONATE Pazopanib Osimertinib mesylate Baricitinib Afatinib 4-[4-[[[[4-Chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl-2-pyridinecarboxamide hydrate Cabazitaxel Pazopanib Hydrochloride Regorafenib Afatinib dimaleate AZD-9291 Nintedanib Ethanesulfonate Salt 2-mercapto-N-methylbenzamide N-[3-Chloro-4-(3-fluorobenzyloxy)phenyl]-6-iodoquinazolin-4-amine 5-[4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl]-2-furaldehyde 2-Aminoethylmethylsulfone hydrochloride p-Toluenesulfonic acid

  • Lapatinib ditosylate
  • benzenesulfonic acid: N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6 -[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]quinazolin-4-amine: h ydrate
  • N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine bis(4-methylbenzenesulfonate)
  • Lapatinib Ditosilate
  • Lapatinib, Tykerb, GW572016
  • Lapatinib Ditosylate (GW-572016)
  • lapatinib(GW572016)
  • Lapatinib ditosylate hydrate
  • bis(N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(Methylsulfonyl)ethylaMino)Methyl)furan-2-yl)quinazolin-4-aMine) tetrakis(4-Methylbenzenesulfonate) hydrate
  • Lapatinb
  • 4-QuinazolinaMine, N-[3-chloro-4-[(3-fluorophenyl)Methoxy]phenyl]-6-[5-[[[2-(Methylsulfonyl)ethyl]aMino]Methyl]-2-furanyl]-, bis(4-Methylbenzenesulfonate), Monohydrate (9CI)
  • Lapatinib ditosylate Monohydrate
  • Rapatinib bis - toluene sulfonate
  • GW-572016;GW572016
  • Lapatinib xylene sulfonate
  • N-[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-quinazolinamine, 4-methylbenzenesulfonate, hydrate (1:2:1)
  • Lapatinib Ditosylate MonohydrateI
  • N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine bis(4-methylbenzenesulfonate) monohydrate
  • Lapatinib ditosylate hydrat
  • 4-QuinazolinaMine, N-[3-chloro-4-[(3-fluorophenyl)Methoxy]phenyl]-6-[5-[[[2-(Methylsulfonyl)ethyl]aMino]Methyl]-2-furanyl]-, bis(4-Methylbenzenesulfonate), Monohydrate
  • xyene sulfonate lapatinib
  • (N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(Methylsulfonyl)ethylaMino)Methyl)furan-2-yl)quinazolin-4-aMine)bis(4-Methylbenzenesulfonate) hydrate
  • Lapatinib ditosylate N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine bis(4-methylbenzenesulfonate)
  • N-(3-Chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)furan-2-yl)-quinazolin-4-ylamine ditosylate hydrate
  • Lapatinib ditoluenesulfonate monohydrate
  • Lapatinib tosilate
  • Lapatinib tosilate hydrate
  • Lapatinib ditosylate ISO 9001：2015 REACH
  • Lapatinib D4 DitosylateQ: What is Lapatinib D4 Ditosylate Q: What is the CAS Number of Lapatinib D4 Ditosylate
  • Lapatinib p-toluenesulfonate monohydrate
  • GW2016 ditosylate
  • (E)-Ferulic acid-d
  • Lapatinib ditosylate monohydrate|||Lapatinib ditoluenesulfonate monohydrate|||Lapatinib tosilate hydrate|||Lapatinib tosilate|||Tykerb|||Tyverb
  • 388082-78-8
  • 388083-78-8
  • 388082-78-9
  • C29H26ClFN4O4S2C7H8O3
  • C29H26ClFN4O4S2C7H8O3S
  • C41H40ClFN4O11S3
  • C29H26ClFN4O4S2C74H8O3SH2O
  • 2C7H8O3SC29H26ClFN4O4S
  • C29H26ClFN4O4S2C7H8O3SH2O
  • C43H44ClFN4O11S3
  • anti-neoplastic
  • Inhibitors
  • Anti-cancer&immunity
  • Lapatinib
  • API
  • 388082-78-8